TX200
Cell therapy
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STEADFAST NCT04817774 · Kidney Transplant Rejection Prophylaxis Registry: NCT04817774 | 1/2 | Short Term Safety and Tolerability of TX200-TR101 Infusion. (28 days post infusion) 2024-07-11 | Short Term Safety and Tolerability of TX200-TR101 Infusion. (28 days post infusion): Treatment With TX200-TR101 (DL1) — Number of participants with TEAEs < grade 3: 1 Participants; Number of participants with TEAEs >= grade 3: 1 Participants; Number of participants with no TEAEs: 1 Participants | Treatment With TX200-TR101 (DL2) — Number of participants with TEAEs < grade 3: 0 Participants; Number of participants with TEAEs >= grade 3: 0 Participants; Number of participants with no TEAEs: 1 Participants | Treatment With TX200-TR101 (DL3) — Number of participants with TEAEs < grade 3: 0 Participants; Number of participants with TEAEs >= grade 3: 0 Participants; Number of participants with no TEAEs: 1 Participants | Treatment With TX200-TR101 (DL4) — Number of participants with TEAEs < grade 3: 1 Participants; Number of participants with TEAEs >= grade 3: 0 Participants; Number of participants with no TEAEs: 2 Participants | Controls — Number of participants with TEAEs < grade 3: 2 Participants; Number of participants with TEAEs >= grade 3: 0 Participants; Number of participants with no TEAEs: 1 Participants | Donors — Number of participants with TEAEs < grade 3: 0 Participants; Number of participants with TEAEs >= grade 3: 0 Participants; Number of participants with no TEAEs: 13 Participants | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Kidney Transplant Rejection Prophylaxis: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| TX200: this drug | Phase 1/2 | Cell therapy | HLA-A*02 (CAR-Treg) | not yet graded | No reviewed efficacy summary in this indication | |
| Basiliximab (Simulect) | Approved | Monoclonal antibody | IL-2 receptor alpha (IL2RA) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.